Lysosomal Therapeutics

Lysosomal Therapeutics is dedicated to the research and development of innovative small molecules in the field of neurodegenerative diseases, providing new treatment options for patients with severe neurological disorders. Their strategy leverages the clinically validated connection between lysosome-based genetic diseases and neurodegenerative diseases, establishing a unique and effective molecular platform for novel drug discovery. LTI's lead program targets Gaucher-related neurodegeneration, Parkinson's disease, and other synucleinopathies.